Association of time in range with lower extremity atherosclerotic disease in type 2 diabetes mellitus: a prospective cohort study | springermedizin.de

Springer Medizin

nach oben

Erschienen in:

23.03.2022 | Original Article

Association of time in range with lower extremity atherosclerotic disease in type 2 diabetes mellitus: a prospective cohort study

verfasst von: Yaxin Wang, Jingyi Lu, Yun Shen, Jiaying Ni, Lei Zhang, Wei Lu, Wei Zhu, Yuqian Bao, Jian Zhou

Erschienen in: Endocrine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Time in range (TIR) has surfaced as a key continuous glucose monitoring (CGM)—derived metric, which was linked to diabetes-related outcomes. We aimed to investigate the association of TIR with the risk of lower extremity atherosclerotic disease (LEAD) among patients with type 2 diabetes.

Methods

A total of 1351 adult patients with type 2 diabetes were prospectively recruited from a single center in Shanghai, China. TIR was obtained from CGM data at baseline. LEAD was measured with color Doppler ultrasonography. Cox proportion hazard regression analysis was used to assess the association between TIR and the risk of incident/progressive LEAD.

Results

During a median follow-up of 7.4 years, 450 participants developed incident/progressive LEAD. The multivariable-adjusted hazard ratios (HRs) for incident/progressive LEAD across different levels of TIR ( > 85%, 71~85%, 51~70%, and ≤50%) were 1.00, 1.15 (95% confidence interval [CI] 0.87–1.52), 1.37 (95% CI 1.04–1.80) and 1.46 (95% CI 1.10–1.94) (P for trend = 0.004), respectively. With each 10% decrease in TIR, the multivariable-adjusted risk of incident/progressive LEAD increased by 7% (95% CI 1.02–1.11). Similar results were found in the association between TIR and incident LEAD as the secondary outcome (P for trend < 0.001).

Conclusions

The current study found an inverse association of TIR with the risk of LEAD among patients with type 2 diabetes.

Anzeige

Nur mit Berechtigung zugänglich

1.

M.I. Maiorino, S. Signoriello, A. Maio, P. Chiodini, G. Bellastella, L. Scappaticcio, M. Longo, D. Giugliano, K. Esposito, Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials. Diabetes Care 43(5), 1146–1156 (2020)CrossRef

2.

J. Bolinder, R. Antuna, P. Geelhoed-Duijvestijn, J. Kröger, R. Weitgasser, Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 388(10057), 2254–2263 (2016)CrossRef

3.

R.W. Beck, T. Riddlesworth, K. Ruedy, A. Ahmann, R. Bergenstal, S. Haller, C. Kollman, D. Kruger, J.B. McGill, W. Polonsky, E. Toschi, H. Wolpert, D. Price, Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. Jama 317(4), 371–378 (2017)CrossRef

4.

T. Haak, H. Hanaire, R. Ajjan, N. Hermanns, J.P. Riveline, G. Rayman, Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 8(1), 55–73 (2017)CrossRef

5.

G. Grunberger, J. Sherr, M. Allende, T. Blevins, B. Bode, Y. Handelsman, R. Hellman, R. Lajara, V.L. Roberts, D. Rodbard, C. Stec, J. Unger, American Association of Clinical Endocrinology Clinical Practice Guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr. Pr. 27(6), 505–537 (2021)CrossRef

6.

Xie P., Deng B., Zhang X., Li Y., Du C., Rui S., Deng W., Boey J., Armstrong D.G., Ma Y., Deng W. Time in range in relation to amputation and all-cause mortality in hospitalised patients with diabetic foot ulcers. Diabetes Metab. Res. Rev. 38(2), e3498 (2021)

7.

K. Kristensen, L.E. Ögge, V. Sengpiel, K. Kjölhede, A. Dotevall, A. Elfvin, F.K. Knop, N. Wiberg, A. Katsarou, N. Shaat, L. Kristensen, K. Berntorp, Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia 62(7), 1143–1153 (2019)CrossRef

8.

C.B. Olivier, H. Mulder, W.R. Hiatt, W.S. Jones, F.G.R. Fowkes, F.W. Rockhold, J.S. Berger, I. Baumgartner, P. Held, B.G. Katona, L. Norgren, J. Blomster, M.R. Patel, K.W. Mahaffey, Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial. JAMA Cardiol. 4(1), 7–15 (2019)CrossRef

9.

J.A. Barnes, M.A. Eid, M.A. Creager, P.P. Goodney, Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease. Arterioscler Thromb. Vasc. Biol. 40(8), 1808–1817 (2020)CrossRef

10.

M.H. Criqui, V. Aboyans, Epidemiology of peripheral artery disease. Circ. Res 116(9), 1509–1526 (2015)CrossRef

11.

V. Aboyans, J.B. Ricco, M.E.L. Bartelink, M. Björck, M. Brodmann, T. Cohnert, J.P. Collet, M. Czerny, M. De Carlo, S. Debus, C. Espinola-Klein, T. Kahan, S. Kownator, L. Mazzolai, A.R. Naylor, M. Roffi, J. Röther, M. Sprynger, M. Tendera, G. Tepe, M. Venermo, C. Vlachopoulos, I. Desormais, 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur. Heart J. 39(9), 763–816 (2018)CrossRef

12.

K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med 15(7), 539–553 (1998)CrossRef

13.

J. Lu, X. Ma, J. Zhou, L. Zhang, Y. Mo, L. Ying, W. Lu, W. Zhu, Y. Bao, R.A. Vigersky, W. Jia, Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care 41(11), 2370–2376 (2018)CrossRef

14.

A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro 3rd, H.I. Feldman, J.W. Kusek, P. Eggers, F. Van Lente, T. Greene, J. Coresh, A new equation to estimate glomerular filtration rate. Ann. Intern Med 150(9), 604–612 (2009)CrossRef

15.

X. He, J. Su, X. Ma, W. Lu, W. Zhu, Y. Wang, Y. Bao, J. Zhou, The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes. Cardiovasc. Diabetol. 19(1), 40–40 (2020)CrossRef

16.

P.J. Touboul, M.G. Hennerici, S. Meairs, H. Adams, P. Amarenco, N. Bornstein, L. Csiba, M. Desvarieux, S. Ebrahim, R. Hernandez Hernandez, M. Jaff, S. Kownator, T. Naqvi, P. Prati, T. Rundek, M. Sitzer, U. Schminke, J.C. Tardif, A. Taylor, E. Vicaut, K.S. Woo, Mannheim carotid intima-media thickness and plaque consensus (2004–2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc. Dis. 34(4), 290–296 (2012)CrossRef

17.

R.W. Beck, R.M. Bergenstal, T.D. Riddlesworth, C. Kollman, Z. Li, A.S. Brown, K.L. Close, Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 42(3), 400–405 (2019)CrossRef

18.

El Malahi A., Van Elsen M., Charleer S., Dirinck E., Ledeganck K., Keymeulen B., Crenier L., Radermecker R., Taes Y., Vercammen C., Nobels F., Mathieu C., Gillard P., De Block C. Relationship between time in range, glycemic variability, HbA1c and complications in adults with type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 107(2), E570-E581 (2021)

19.

Mayeda L., Katz R., Ahmad I., Bansal N., Batacchi Z., Hirsch I.B., Robinson N., Trence D.L., Zelnick L., de Boer I.H. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res. Care 8(1), e000991 (2020)

20.

J.H. Yoo, M.S. Choi, J. Ahn, S.W. Park, Y. Kim, K.Y. Hur, S.M. Jin, G. Kim, J.H. Kim, Association between continuous glucose monitoring-derived time in range, other core metrics, and albuminuria in type 2 diabetes. Diabetes Technol. Ther. 22(10), 768–776 (2020)CrossRef

21.

Q. Guo, P. Zang, S. Xu, W. Song, Z. Zhang, C. Liu, Z. Guo, J. Chen, B. Lu, P. Gu, J. Shao, Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of hba1c in chinese type 2 diabetes. J. Diabetes Res 2020, 5817074 (2020)PubMedPubMedCentral

22.

M.Y. Kim, G. Kim, J.Y. Park, M.S. Choi, J.E. Jun, Y.B. Lee, S.M. Jin, K.Y. Hur, J.H. Kim, The association between continuous glucose monitoring-derived metrics and cardiovascular autonomic neuropathy in outpatients with type 2 diabetes. Diabetes Technol. Ther. 23(6), 434–442 (2021)CrossRef

23.

J. Lu, X. Ma, Y. Shen, Q. Wu, R. Wang, L. Zhang, Y. Mo, W. Lu, W. Zhu, Y. Bao, R.A. Vigersky, W. Jia, J. Zhou, Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol. Ther. 22(2), 72–78 (2020)CrossRef

24.

E. Selvin, T.P. Erlinger, Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 110(6), 738–743 (2004)CrossRef

25.

C.P. Yang, C.C. Lin, C.I. Li, C.S. Liu, C.H. Lin, K.L. Hwang, S.Y. Yang, T.C. Li, Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes. Cardiovasc. Diabetol. 19(1), 4 (2020)CrossRef

26.

Y. Shen, D. Dai, J. Lu, Y. Wang, W. Zhu, Y. Bao, G. Hu, J. Zhou, Visit-to-visit variability of glycated albumin was associated with incidence or progression of lower extremity atherosclerotic disease. Cardiovasc. Diabetol. 19(1), 211 (2020)CrossRef

27.

C. Zhang, M. Tang, X. Lu, Y. Zhou, W. Zhao, Y. Liu, Y. Liu, X. Guo, Relationship of ankle-brachial index, vibration perception threshold, and current perception threshold to glycemic variability in type 2 diabetes. Medicine 99(12), e19374 (2020)CrossRef

28.

A. Ceriello, K. Esposito, L. Piconi, M.A. Ihnat, J.E. Thorpe, R. Testa, M. Boemi, D. Giugliano, Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57(5), 1349–1354 (2008)CrossRef

29.

R.W. Beck, R.M. Bergenstal, P. Cheng, C. Kollman, A.L. Carlson, M.L. Johnson, D. Rodbard, The relationships between time in range, hyperglycemia metrics, and HbA1c. J. Diabetes Sci. Technol. 13(4), 614–626 (2019)CrossRef

30.

J. Lu, X. Ma, L. Zhang, Y. Mo, W. Lu, W. Zhu, Y. Bao, W. Jia, J. Zhou, Glycemic variability modifies the relationship between time in range and hemoglobin A1c estimated from continuous glucose monitoring: A preliminary study. Diabetes Res Clin. Pr. 161, 108032 (2020)CrossRef

31.

T.W. Rooke, A.T. Hirsch, S. Misra, A.N. Sidawy, J.A. Beckman, L.K. Findeiss, J. Golzarian, H.L. Gornik, J.L. Halperin, M.R. Jaff, G.L. Moneta, J.W. Olin, J.C. Stanley, C.J. White, J.V. White, R.E. Zierler, 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 58(19), 2020–2045 (2011)CrossRef

Titel: Association of time in range with lower extremity atherosclerotic disease in type 2 diabetes mellitus: a prospective cohort study
verfasst von: Yaxin Wang
Jingyi Lu
Yun Shen
Jiaying Ni
Lei Zhang
Wei Lu
Wei Zhu
Yuqian Bao
Jian Zhou
Publikationsdatum: 23.03.2022
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-03038-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Anzeige

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen